Nanobac Pharmaceuticals Price To Sales vs. Total Asset
| NNBP Stock | USD 0.0001 0.00 0.00% |
Nanobac Pharmaceuticals Price To Sales Ratio |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.15 | 0.16 |
|
| |||||
| Operating Profit Margin | 264 | 251 |
|
| |||||
| Return On Equity | 2.63 | 2.51 |
|
|
For Nanobac Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nanobac Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nanobac Pharmaceuticals Incorporated utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nanobac Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nanobac Pharmaceuticals Incorporated over time as well as its relative position and ranking within its peers.
Nanobac |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nanobac Pharmaceuticals. If investors know Nanobac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nanobac Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Revenue Growth 0.866 | Return On Assets (0.37) |
The market value of Nanobac Pharmaceuticals is measured differently than its book value, which is the value of Nanobac that is recorded on the company's balance sheet. Investors also form their own opinion of Nanobac Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Nanobac Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nanobac Pharmaceuticals' market value can be influenced by many factors that don't directly affect Nanobac Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nanobac Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nanobac Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nanobac Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Nanobac Pharmaceuticals Total Asset vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Nanobac Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Nanobac Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Nanobac Pharmaceuticals Incorporated is rated below average in price to sales category among its peers. It is rated below average in total asset category among its peers fabricating about 1,019,784 of Total Asset per Price To Sales. At this time, Nanobac Pharmaceuticals' Price To Sales Ratio is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Nanobac Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Nanobac Total Asset vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Nanobac Pharmaceuticals |
| = | 7.08 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Nanobac Pharmaceuticals |
| = | 7.22 M |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Nanobac Total Asset Comparison
Nanobac Pharmaceuticals is currently under evaluation in total asset category among its peers.
Nanobac Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Nanobac Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nanobac Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Nanobac Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Nanobac Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -5.1 M | -5.4 M | |
| Net Loss | -7.6 M | -7.9 M | |
| Income Before Tax | -7.6 M | -7.9 M | |
| Total Other Income Expense Net | -1.9 M | -1.8 M | |
| Net Loss | -7.6 M | -7.9 M | |
| Net Loss | -7.6 M | -7.9 M | |
| Change To Netincome | 4 M | 2.5 M | |
| Net Loss | (0.02) | (0.02) | |
| Income Quality | 0.12 | 0.19 | |
| Net Income Per E B T | 0.91 | 0.84 |
Nanobac Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Nanobac Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nanobac Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nanobac Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Nanobac Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Use Investing Themes to Complement your Nanobac Pharmaceuticals position
In addition to having Nanobac Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Processed Foods Thematic Idea Now
Processed Foods
Companies producing and distributing processed foods to retail sectors. The Processed Foods theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Processed Foods Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.